A Phase 2 interventional study of Virtual Reality in Burn, sponsored by National Institute of General Medical Sciences (NIGMS). Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-09-01.
Sponsored by National Institute of General Medical Sciences (NIGMS) · Phase 2, Interventional, and Health services research
The purpose of the research is to see whether a low dose of ketamine, a medication used to reduce pain, enhances the effectiveness of a virtual reality video game, which is used as a form of distraction from pain during a painful burn care procedure.
This study is conducted in a hospital setting. It is a randomized controlled trial comparing the use of virtual reality distraction (VRD) and standard pain medications to the use of VRD, standard pain medications and a single low dose of ketamine as a means to reduce pain during a painful procedure in patients in the hospital.
719 studies on the registry are indexed under Burns; 145 are open to participants now.
This study's enrollment of 3 is below the median of 40 across 524 interventional studies indexed under Burns.
Browse Burns studies →National Institute of General Medical Sciences (NIGMS) is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Comparing Virtual Reality during burn care with Ketamine
Behavioral: Virtual Reality
Comparing virtual reality during burn care without Ketamine.
Behavioral: Virtual Reality
The patient will receive virtual reality during a burn care procedure
Graphic Rating Scale (GRS) is a questionnaire consists of three subjective pain ratings, one subjective anxiety rating, and one rating of fun using the 0-10.
Time frame: 1 day (Immediately following burn care )
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of General Medical Sciences (NIGMS)